Clinical Trial Search

Primary: Favorable Clinical Outcomes (FCl) — 170; 132 Participants

Primary: Efficacy Endpoint: The Percent of Patients Off Class I or III Antiarrhythmic Drugs and Out of AF as Determined by 24 Hour Holter Recording at 9 Months — 42.6 percentage…

Primary: Number of Participants for Global Response (Based on Clinical and Microbiological Success or Failure) at End of Treatment — 26; 18 participants

Primary: Efficacy Endpoint: The Percent of Patients Off Class I and/or III Antiarrhythmic Drugs and Out of Atrial Fibrillation as Determined by 24 Hour Holter Recording Conducted…

Primary: Absolute Vertebral Body Height Restoration as a Percent (Post-procedure Change From Baseline) — 9.72; 11.77; 8.14; 9.07 percent change — p=0.430

Primary: Overall Participant Response — 44; 1; 10 Participants

Primary: Sustained Virologic Response Rates — 29; 14 participants

Primary: Recurrence Free Survival — 9.6; 16.4 months — p=0.056

Primary: Proportion of Participants With Residual CIN2+ — 18; 29; 25 Participants

Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 1; 1; 2; 1 Participants

Primary: Normalization in Urinary Free Cortisol in Patients With Endogenous Cushing's Syndrome. — .30 proportion of subjects meeting endpoint — p=0.0154

Primary: The Percentage of Subjects Infected With Gyrase A (gyrA) Serine 91 Genotype of Neisseria Gonorrhoeae (N. Gonorrhoeae) With Microbiological Cure — 100 percentage of…

Primary: Number of Patients Who Experienced 50% or Greater Wound Healing — 13; 7; 4 Participants

Primary: Number of Participants With Confirmed Complete Molecular Response (CMR) — 34 Participants

Primary: The Rates of Complete Symptom Relief — 152; 157 participants — p=<0.05

Primary: Number of Participants Completing HCV Treatment — 3; 6 Participants

Primary: Llocoregional Recurrence — 27 Participants

Primary: Number of Participants Achieving Clinical Cure — 5 Participants

Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants

Primary: Clinical Sensitivity and Specificity for Microorganism Detection as Compared to Routine Microbiology and Other Reference Methods Including PCR and Sequencing — 91.4…

Primary: Number of Participants Who Complete Treatment With >90% Adherence — 223; 211 Participants — p=0.07

Primary: Clinical Response Within 48 Hours — 28 Participants

Primary: Macrolide Resistance Determinants — 110.3; 167.53 normalized determinants/million reads — p=0.1026

Primary: Objective Response — 4; 1; 5; 3 Participants

Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat

Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…

Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L

Primary: Number Participants With 100% Clearance — 12; 13 Participants

Primary: Sustained Viral Response (SVR) — 30; 12.8 percentage of Participants — p=0.07

Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants